Organic Active Ingredients TRIZ Cases

Antisense oligonucleotides block aberrant splice sites in ABCA4 pre-mRNA, correcting transcripts to halt Stargardt disease progression.

Replacing cyanide with carbon-based leaving groups boosts HNO yield at neutral pH without toxic byproducts.

Novel compounds form a covalent adduct with the flavin ring of FAD to resolve metabolic stability and clearance issues.

A tert-butyl alcohol co-solvent system enables rapid reconstitution of dantrolene sodium formulations.

Administering a melatonin agonist treats sleep disorders in cardiac patients with superior cervical ganglion dysfunction without causing drug addiction.

D-psicose activates glucokinase by promoting its transfer from the nucleus to the cytoplasm, addressing uncontrolled blood glucose in type 2 diabetes.

Balanced histidine, lysine, and threonine ratios treat pervasive developmental disorders while maintaining patient compliance with normal diets.

Mutant photosynthetic bacteria synthesize lycogen to overcome low lycopene bioavailability and limited natural extraction yields.

Small molecule inhibitors bind anti-apoptotic Bcl-2 proteins to overcome chemotherapy resistance and restore treatment efficacy.

Oral and topical pyrimidine derivatives block JAK enzymes locally, reducing systemic immunosuppression while treating ulcerative colitis and dermatitis.

A 1:1 adduct of sickle hemoglobin binds a single aldehyde molecule to form a conformationally stable complex that inhibits the sickled configuration.

Segmenting the dosage form into adhesive, intermediate, and hydrophobic layers resolves short residence time and washout by saliva.

Ionic liquid additives reduce Amphotericin B nephrotoxicity while maintaining antifungal efficacy against drug-resistant Candida auris.

Targeted STING agonist delivery concentrates cytokines in tumors while preventing adverse systemic immune responses.

Combining squirrel fibroma virus with reovirus creates a pharmaceutical composition that selectively infects cancer cells while sparing normal human tissue.

Benzenesulfonamides selectively inhibit perforin activity, avoiding the broad biological effects of non-selective inhibitors.

ROCK-PDK1 inhibitors selectively suppress TNFα and interferon production to reduce inflammatory stress without causing significant side effects.

Thiol isomerase inhibitors block cytokine production and attenuate food allergy symptoms by regulating mast cell activation.

Administering TNF antagonists alongside CD3 antibodies prevents severe cytokine release syndrome in patients intolerant to standard IL-6 treatments.

Topical pyrimidine compounds inhibit JAK kinases locally, avoiding systemic immunosuppression while treating atopic dermatitis.

Combining Cannabis sativa extracts with Calendula officinalis eliminates synthetic cytotoxicity while treating atopic dermatitis.

Combining cholesterol-conjugated nucleic acids with chloroquine overcomes systemic barriers and enhances therapeutic efficacy in cancer treatment.

Engineered T cells with PDCD1 gene disruption overcome PD-1 inhibition to maintain effector function and persistence during adoptive transfer.

Lithium triethylborohydride reduces tetrahydropyrido-dioxazine precursors to form 1,3-diazo-4-oxa-bicyclic derivatives.

Synergistic omega-6 to omega-3 fatty acid blend enhances nutritional bioavailability through balanced composition.

1,5-diazacarbazole compounds inhibit checkpoint kinase 1 to address insufficient efficacy and specificity in existing cancer therapies.

A blend of high amylose starch, cross-linked hydroxypropylated amylopectin, and pre-gelatinized common starch controls active pharmaceutical ingredient release.

A nonionic triblock copolymer delivery system enhances bioavailability of low solubility active agents through solubilization and permeability mechanisms.

Anti-DR5 antibody targets death receptor 5 to kill cancer cells while avoiding normal cell toxicity caused by non-specific binding.

Fermented mare milk compositions strengthen the immature mammal immune system using defined bacterial strains to mitigate infections.

A bone delivery system uses a segmented covering to hold and release therapeutic agents at surgical sites.

Combining citicoline and nicotinamide in an aqueous solution overcomes low oral bioavailability, slowing retinal nerve fiber loss.

Segmented gut microbiota analysis predicts Clostridium difficile infection treatment response, avoiding prolonged ineffective antibiotic trials.

Segmenting racemic bupropion isolates the active (S)-enantiomer, reducing adverse effects while maintaining therapeutic coverage.

Pyrimidinyl tricyclic enone derivatives inhibit RORγ activity, reducing IL-17 overproduction and addressing inflammatory diseases.

A long-acting PTH compound normalizes bone turnover markers and stabilizes BMD Z-scores through intermittent dosing cycles.

Azetidine estrogen receptor modulators degrade ER-alpha to overcome treatment resistance in metastatic breast cancer.

Combines anti-c-Met antibodies with aminoheteroaryl compounds to inhibit tumor growth.

Combining a PDE1B selective inhibitor with a second compound modulates neuronal signaling pathways to treat psychiatric disorders.

Internally cross-linked p53 transactivation domain-based inhibitor peptides target HDM2 and HDMX to restore tumor suppressor activity.

Heterocyclic compounds modulate gamma secretase to reduce amyloid beta, addressing limited effectiveness of existing inhibitors.

Glucocorticoid receptor antagonists block cortisol signaling to reduce anxiety and withdrawal symptoms in addiction therapy.

Selective PDE9 inhibition elevates cGMP to improve cognitive function without metabolic side effects of antipsychotics.

Dual inhibitor compounds target c-fms and c-kit receptors to modulate receptor protein tyrosine kinase activity.

A citrate-containing priming solution fills the extracorporeal blood circuit to provide anticoagulation without heparin.

PEG-modified diphenhydramine reduces blood-brain barrier crossing, minimizing drowsiness while maintaining antihistaminic activity.

Bouvardin analogs inhibit ribosome activity to block cancer cell growth while reducing toxicity through structural modifications.